泊馬度胺

泊馬度胺
臨床資料
商品名（英語：Drug nomenclature）	Pomalyst, Imnovid
AHFS/Drugs.com	Monograph
MedlinePlus	a613030
核准狀況	歐 EMA: yes; 美 DailyMed: Pomalidomide;
懷孕分級	澳: X (高風險) ; ;
給藥途徑	By mouth
ATC碼	L04AX06 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）; Rx-to 3Donly;
藥物動力學數據
生物利用度	73% (at least)
血漿蛋白結合率	12–44%
藥物代謝	Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
生物半衰期	7.5 hours
排泄途徑	Urine (73%), faeces (15%)
識別資訊
	IUPAC命名法 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; ;
CAS號	19171-19-8
PubChem CID	134780;
IUPHAR/BPS	7348;
DrugBank	DB08910 ;
ChemSpider	118785 ;
UNII	D2UX06XLB5;
KEGG	D08976 ;
ChEMBL	ChEMBL43452 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID40893458 ;
ECHA InfoCard	100.232.884
化學資訊
化學式	C13H11N3O4
摩爾質量	273.25 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
手性	Racemic mixture
	SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N;
	InChI InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ; Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ;

泊馬度胺（英語：Pomalidomide，商品名有Pomalyst、Imnovid）是一種含氮有機化合物，化學式為C₁₃H₁₁N₃O₄，可作為化療藥物^[7]，用於治療多發性骨髓瘤和AIDS相關的卡波西肉瘤^[6]。

參考文獻

^ Pomalidomide (Pomalyst) Use During Pregnancy. Drugs.com. 14 May 2020 [21 September 2020]. （原始內容存檔於25 January 2021）.
^ Pomalidomide Medicianz/ Pomalimed/ Pomalidomide Medsurge (Medicianz Healthcare Pty Ltd). Therapeutic Goods Administration (TGA). 5 December 2022 [9 April 2023]. （原始內容存檔於18 March 2023）.
^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. （原始內容存檔於10 April 2023）.
^ Product information.
^ Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC). (emc). 16 June 2020 [21 September 2020]. （原始內容存檔於26 October 2020）.
^ ^6.0 ^6.1 Pomalyst- pomalidomide capsule. DailyMed. 7 December 2017 [21 September 2020]. （原始內容存檔於20 October 2020）.
^ ^7.0 ^7.1 Imnovid EPAR. European Medicines Agency (EMA). 17 September 2018 [21 September 2020]. （原始內容存檔於27 October 2020）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties (PDF). Celgene Europe Ltd.: 22. [21 August 2016]. （原始內容存檔 (PDF)於27 June 2016）.
^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. （原始內容存檔於2023-08-03）（巴西葡萄牙語）.

[Drugs.com_pregnancy-1] Pomalidomide (Pomalyst) Use During Pregnancy. Drugs.com. 14 May 2020 [21 September 2020]. （原始內容存檔於25 January 2021）.

[2] Pomalidomide Medicianz/ Pomalimed/ Pomalidomide Medsurge (Medicianz Healthcare Pty Ltd). Therapeutic Goods Administration (TGA). 5 December 2022 [9 April 2023]. （原始內容存檔於18 March 2023）.

[3] Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. （原始內容存檔於10 April 2023）.

[4] Product information.

[5] Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC). (emc). 16 June 2020 [21 September 2020]. （原始內容存檔於26 October 2020）.

[Pomalyst_PI-6] 6.0 ^6.1 Pomalyst- pomalidomide capsule. DailyMed. 7 December 2017 [21 September 2020]. （原始內容存檔於20 October 2020）.

[Imnovid_EPAR-7] 7.0 ^7.1 Imnovid EPAR. European Medicines Agency (EMA). 17 September 2018 [21 September 2020]. （原始內容存檔於27 October 2020）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[8] Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties (PDF). Celgene Europe Ltd.: 22. [21 August 2016]. （原始內容存檔 (PDF)於27 June 2016）.

[9] Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. （原始內容存檔於2023-08-03）（巴西葡萄牙語）.

[7]

[6]

[1]

[2]

[3]

[4]

[5]

[8]